Meeting Banner
Abstract #1538

False-Negative MRI Biomarkers of Tumour Response to Targeted Cancer Therapeutics

Jessica K.R. Boult1, Yann Jamin1, Vivien Jacobs2, Lesley D. Gilmour1, Simon Walker-Samuel1, Jane Halliday2, Paul Elvin2, Anderson J. Ryan2, John C. Waterton2, Simon P. Robinson1

1CRUK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 2AstraZeneca, Alderley Park, Cheshire, United Kingdom

The use of pharmacodynamic biomarkers, including imaging biomarkers, is now desirable for the evaluation of novel molecularly targeted therapeutics in oncology. Before their deployment in clinical trials, such imaging biomarkers require evaluation. Here we describe two preclinical studies in which emerging MRI biomarkers were correlated with histology to assess tumour response to Src kinase or VEGFR2 inhibition. In both studies, treatment resulted in pathological target inhibition, but the corresponding imaging biomarkers failed to show the anticipated change. Reporting of such negative preclinical imaging biomarker responses is informative for clinical trial design.

Abstract PDF Poster PDF

Keywords

abandoned acknowledge acknowledgments activated activity adduct adhesion administered alone animal animals anti assess assessed axial biomedical birdcage blood breast cancer causing clear clinical coefficient cohort cohorts coil contrast daily days delivery deployment describe described detection diffusion division echoes efficacy either elicited elucidate emerging equivalent established evaluate evaluation expected expression failed false focal formation fractional frozen funding genes highly histology horizontal hypoxia identical identify illustrates index induced inhibition inhibitor injected invasive irrespective john killed kingdom mammary maps matrix measured mice minute minutes mistaken mobility molecular natl negative nevertheless novel observations overall parametric park particles pathology pathway pathways pattern perfusion period positioned predominantly press prior pronounced prostate quantification quantitative radiotherapy rats received reduction repeated require response revealed risk section sections setting significantly slices staining studies substrates success support surrey susceptibility switched system table target targeted temporal therapeutics transient transition treated treatment trials true typically undertaken uptake validate vehicle vessel volume walker whole workman